Tag: Eli Lilly

FDA Accepted Eli Lilly Application to Enter CID Pilot Meeting Program

Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) has accepted its application to enter the Complex Innovative Trial Designs (CID) Pilot Meeting Program, an initiative which ...

FDA Approved Eli Lilly’s Taltz® Injection

Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved Taltz® (ixekizumab) injection 80 mg/mL for the treatment of adults with active ankylosing spondylitis (AS)...

Biosimilar Teriparatide Launches in Europe by Gedeon Richter

gedeon-richter
A biosimilar to Eli Lilly’s Forsteo, biosimilar teriparatide, has been launched across Europe by Gedeon Richter following the patent expiration of the reference product, it was revealed on Aug. 20, 20...

Arbitration Panel Ruled in Favor of Eli Lilly in Complaint Filed by Adocia

A Chicago-based arbitration panel has ruled in favor of Eli Lilly and Company (NYSE: LLY) in a claim filed by Adocia S.A. over the companies' prior collaboration on rapid-acting insulin. The panel of ...

Positive Results for Eli Lilly’s Emgality® from CONQUER Study Announced

Eli Lilly and Company announced that Emgality® (galcanezumab-gnlm) met the primary and all key secondary outcomes in CONQUER, a Phase 3 study evaluating the efficacy and safety of Emgality in the prev...

Eli Lilly Announced Positive Phase 3 Data for Emgality®

lilly
Eli Lilly announced that the New England Journal of Medicine published positive Phase 3 study results of Emgality® (galcanezumab-gnlm) for the treatment of episodic cluster headache. In this study, Em...

Amgen, Merck, Eli Lilly Sue the U.S. Government to Block Rule Requiring Drug Prices in TV Ads

Three pharmaceutical companies sued the federal government to block a proposal requiring drug manufacturers include the list price of prescription drugs in television ads, the latest volley by the ind...

BI and Eli Lilly Announced Detailed Findings from the CAROLINA® Trials

Boehringer Ingelheim and Eli Lilly and Company announced detailed findings from the CAROLINA® trial demonstrating that Tradjenta® (linagliptin) did not increase cardiovascular risk compared with glime...

FDA Accepted Boehringer, Lilly NDA for Triple Combination Tablet for Adults with Type 2 Diabetes

diabetes drugs
The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for the investigational fixed-dose combination tablet of empagliflozin, linagliptin and metformin extended relea...

FDA Approved Eli Lilly’s Emgality

The U.S. Food and Drug Administration approved Emgality (galcanezumab-gnlm) solution for injection for the treatment of episodic cluster headache in adults.  “Emgality provides patients with the firs...

Lilly’s Insulin Lispro Injection List Price Announced

Eli Lilly and Company's Insulin Lispro Injection is now available for order in pharmacies for people who use Lilly's rapid-acting insulin and need a lower-cost option. Lilly's Insulin Lispro Injection...

FDA Approved Eli Lilly Cyramza for Hepatocellular Carcinoma

lilly
On May 10, 2019, the Food and Drug Administration approved ramucirumab (CYRAMZA®, Eli Lilly and Company) as a single agent for hepatocellular carcinoma (HCC) in patients who have an alpha fetoprotein ...

Eli Lilly Q1 Profit Tripled

Eli Lilly and Co reported lower-than-expected sales for its top-selling diabetes drug Trulicity and cut its full-year revenue forecast as it sees further hits from price declines in the United States,...

Eli Lilly Selling Chinese Rights to Two Legacy Antibiotics

Eli Lilly has inked a $375 million deal with China-based Eddingpharm for the rights to two legacy antibiotic medicines and manufacturing facility in Suzhou, China. The sale of off-patent drug asset...

Prozac to Withdraw from Taiwan in April

The popular antidepressant Prozac is to be permanently removed from pharmacy shelves this April in Taiwan, announced the drug's Taiwanese manufacturer Zuellig Pharma (裕利藥廠) last week, reported CNA. ...

Priority Review for Lilly’s Preventing Cluster Headache Injection

Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for its supplemental Biologics License Application (sBLA) for Emgality® (galcanezumab...